Banking the peptide industry is a file problem, not a sector problem.

Peptide businesses are among the most misunderstood merchants in the payments industry. A compliance officer at a bank or acquirer sees the word "peptide" and, in the absence of anything else, mentally files it next to unapproved pharmaceuticals, grey-market nootropics, and the anabolic corner of the supplement world. The application is declined in minutes, often without a human ever reading the product catalogue, the licences, or the laboratory certificates sitting in the appendix.

That reaction is not irrational. Over the last decade a large volume of peptide sales genuinely has taken place through websites making explicit therapeutic claims about substances that no regulator has approved for human use, shipped internationally with no import documentation, and processed through accounts opened under a description that had nothing to do with what was actually being sold. Every acquirer that got burned on that traffic wrote a rule, and the rule was blunt: decline the keyword.

The consequence is that legitimate operators — a licensed compounding pharmacy network, a GMP peptide ingredient supplier selling business-to-business to formulators, a cosmetic brand using signal peptides in an approved topical, a telehealth platform where every order is preceded by a licensed prescriber consultation, a CDMO running solid-phase peptide synthesis under an ISO-certified quality system — are all sorted into the same bucket as the worst actor in the category.

This is precisely the kind of problem that is solved with a file rather than with luck. Underwriting is not a moral judgement about your sector; it is a risk-adjusted decision about a specific legal entity, its ownership, its products, its claims, its geography, its chargeback history, and its ability to prove all of the above. When those elements are documented, mapped to the right institution, and presented in the sequence the risk committee reads them in, peptide companies are approved routinely.

The difference between an approval and a decline is rarely a difference in the underlying business. It is a difference in preparation. A company that applies cold, describing itself vaguely as "health and wellness e-commerce", is asking the underwriter to guess — and a risk officer who has to guess always guesses down. A company that arrives with a product-by-product classification, a claims audit, a supply chain map, a licence pack and a chargeback model is asking the underwriter to verify, which is a completely different task.

The other structural mistake is applying to the wrong institution. Most high-street banks and mainstream acquirers have hard-coded prohibitions that no amount of documentation will overcome, because the prohibition lives in their card scheme registration terms or their own regulator-facing risk appetite statement. Sending a perfect file to an institution whose policy excludes your category is not persuasion, it is a wasted decline that then has to be disclosed on the next application.

This guide is about doing it the other way. It covers how peptide business models are actually classified, which merchant category codes apply, what a bank's onboarding committee tests, how to build a payment stack that survives a processor exit, how to structure the corporate entity and its banking geography, what compliant marketing copy looks like, how chargebacks and refunds are controlled in this vertical, and what the realistic timeline and cost of getting properly banked looks like.

The short version of the thesis: peptide banking is not easy because someone knows a friendly bank. It is easy when the business is legible. Our job at Xavion Capital is to make it legible — and then to route it to the institutions inside our network of 120+ banking and payment partners whose written risk appetite already covers exactly the model you operate.

"Peptide company" describes at least five distinct businesses with radically different risk profiles. Getting your own model named correctly, in the underwriter's own vocabulary, is the single highest-leverage thing you can do before an application.

Research-use-only (RUO) peptide supply. Sale of synthesised peptides to laboratories, universities, biotech companies and research institutions, labelled and sold strictly for in-vitro or preclinical research, not for human or veterinary use. Risk here is driven almost entirely by two things: whether the website and packaging maintain the research-use position consistently, and whether the customer base is genuinely institutional or is in practice individual consumers buying for personal use. An RUO business that sells B2B with purchase orders, institutional invoices and account applications is a very different proposition from an RUO business taking anonymous card payments from consumer inboxes at two in the morning.

Prescriber-led and compounded therapeutics. Telehealth platforms, medical clinics, and compounding pharmacy networks where a licensed clinician evaluates a patient and a licensed pharmacy dispenses. This is the most bankable peptide model in existence when the chain of licensure is documented, because it is not really a peptide business to an underwriter — it is a regulated healthcare business, and healthcare has established acquiring infrastructure, established MCCs, and mature underwriting norms.

Cosmetic and topical peptides. Skincare and personal care brands using peptides such as palmitoyl tripeptides, acetyl hexapeptide and copper peptides in leave-on and rinse-off formulations. These are cosmetics, regulated as cosmetics, and are among the easiest categories to bank — provided the marketing copy stays inside cosmetic claims and does not drift into drug claims about structure and function of the body, which is the single most common way a cosmetic brand accidentally reclassifies itself as an unapproved drug in the eyes of a regulator and an acquirer.

Ingredient supply, APIs and B2B distribution. Sale of peptide raw materials, active pharmaceutical ingredients and excipients to formulators, contract manufacturers and brands. Almost always invoice-and-transfer rather than card, which changes the entire banking conversation: the requirement is correspondent banking, trade documentation and cross-border payment capacity, not an acquiring MID.

Manufacturing and CDMO. Solid-phase peptide synthesis, purification, lyophilisation, fill-finish and analytical services under a quality management system, serving pharmaceutical and biotech clients. This is industrial manufacturing with a technical export profile. It banks like manufacturing, needs trade finance and FX rather than card acquiring, and is usually the easiest of the five to place — the difficulty is volume, currency pairs and customer geography rather than category risk.

Most real companies are a blend. A group might run a cosmetic brand, an RUO catalogue and a B2B ingredient line under one legal entity, with a single bank account and a single merchant account handling all of it. That commingling is the problem, not the individual lines. The moment an underwriter sees a consumer card flow, a research catalogue and an ingredient export business sharing one settlement account, they cannot risk-assess any of them, and the safe answer for them is no.

The fix is separation. Distinct legal entities or at minimum distinct websites, distinct merchant accounts and distinct settlement accounts per model, each with its own descriptor, its own MCC, its own terms, and its own refund policy. This costs a little more to run and it converts an unbankable group into three or four cleanly bankable businesses. In practice it is the recommendation we make most often, and it is the one that changes outcomes most reliably.

Before any application goes out, we write a one-page model statement that names which of the five you are, what percentage of revenue each line represents, and how the lines are separated operationally. Underwriters read it first, and it reframes the entire file from "peptides" to a specific, priceable business.

The merchant category code assigned to your merchant account determines interchange, determines which scheme monitoring programmes you fall under, determines whether issuing banks decline your transactions at higher rates, and — critically — determines whether an acquirer's automated policy engine even lets a human look at your application.

Getting the MCC right is not about finding a lenient one. Deliberately boarding under a code that misdescribes your business is transaction laundering in the eyes of the card schemes, and the penalties are severe: immediate termination, placement on the MATCH list, scheme fines that flow through to the acquirer, and permanent difficulty obtaining processing thereafter. Every operator who has ever been offered a "clean" MCC by an unregulated intermediary should understand that the offer is not a shortcut, it is a fuse.

The codes that legitimately apply across the peptide landscape include those for drug stores and pharmacies, health practitioners and medical services, cosmetic stores, chemicals and allied products, industrial supplies, and health and beauty spas — each mapping to one of the five models above. A prescriber-led telehealth platform boards under a healthcare code. A cosmetic brand boards under a cosmetics or general retail code. A B2B ingredient supplier that does take card boards under chemicals or industrial supplies. An RUO catalogue selling to institutions is a chemicals and allied products merchant, not a nutritional supplement merchant.

Descriptors matter almost as much. The billing descriptor that appears on a cardholder statement is one of the largest single drivers of chargeback volume in every high-risk vertical. A descriptor that does not obviously match the brand the customer bought from produces "I don't recognise this charge" disputes at multiples of the normal rate, and those disputes count against you regardless of whether the underlying sale was perfect. The descriptor must contain a recognisable brand token and a working customer-service phone number, and it must be tested on a live transaction before volume is switched on.

Card-not-present, cross-border and recurring flags all layer additional cost and scrutiny on top. A US-domiciled cardholder buying from an entity acquired in another region generates a cross-border transaction with higher interchange and higher decline rates from issuers running their own geographic risk rules. This is one of the reasons local acquiring in your primary sales market usually outperforms a single offshore MID, even when the offshore MID is cheaper on headline rate.

Then there is the scheme monitoring layer. Visa and Mastercard both operate dispute and fraud monitoring programmes with defined thresholds, and both operate integrity programmes covering merchants selling products in restricted categories. Falling into one of these programmes triggers remediation timelines, fines, and — if unresolved — termination. Peptide merchants are watched more closely than average, so the operating discipline described later in this guide is not optional hygiene; it is what keeps you below the threshold that starts the clock.

Practically, the classification exercise we run before an application looks like this: every SKU is listed; each SKU is assigned a regulatory classification (cosmetic, supplement, RUO chemical, prescription medicine, device, ingredient); each classification is mapped to an appropriate MCC; revenue is split by classification; and any SKU that cannot be cleanly classified is either reformulated, relabelled, or moved to a different entity. What comes out is a document that an underwriter can check in ten minutes instead of a catalogue they have to interpret.

That document is often the reason a file gets approved. It removes ambiguity, and ambiguity is the thing that kills peptide applications.

Every bank and acquirer runs a version of the same test. The vocabulary differs, the weighting differs, but the substance is remarkably consistent, and once you have seen enough committee packs the pattern becomes predictable enough to prepare for.

Legitimacy of the entity. Incorporation documents, registers of directors and shareholders, ultimate beneficial ownership down to natural persons, proof of registered and operating address, and evidence the company actually operates where it says it does. Nominee arrangements, layered holdcos with no economic substance, and UBOs who cannot be verified are the fastest route to a decline in any regulated onboarding.

Legitimacy of the product. Product list with classifications, ingredient and specification sheets, certificates of analysis from an accredited laboratory, manufacturing site information, quality certifications where applicable, and — where the model requires them — pharmacy licences, wholesaler distribution authorisations, clinician licences, import permits and facility registrations.

Legitimacy of the claims. A screenshot pack of the live website, landing pages, email flows and any paid advertising creative, cross-checked against what the classification permits. This is where more peptide applications fail than anywhere else, and it is the subject of its own section below.

Legitimacy of the flow. Twelve months of processing statements if you have them: gross volume, average ticket, refund rate, chargeback rate and reason codes, decline rate, and the split between new and returning customers. If you are pre-revenue, a defensible forecast with the assumptions written down, and personal or affiliate-company statements that evidence the operator's track record.

Legitimacy of the money. Source of funds and source of wealth for the UBOs, expected inbound and outbound flows by counterparty type and geography, banking history including prior closures, and a clear explanation of intercompany movements. Undisclosed prior account closures discovered later are treated as deliberate concealment, and they end relationships that documentation would have preserved.

Operational control. Who runs compliance, what the refund and cancellation policy says, how customer service is staffed and how quickly it responds, what fraud tooling is deployed, how age and eligibility are verified where relevant, how shipping restrictions by jurisdiction are enforced at checkout, and what happens when a regulator or a scheme asks a question.

Resilience. Whether the business survives losing its primary processor. An underwriter who believes you have no alternative rail knows that any problem becomes their problem immediately, which paradoxically makes them more cautious. Merchants with a documented secondary arrangement are underwritten more favourably, not less.

The file we prepare answers all eight in the order above, with an executive summary at the front that states the model, the volumes, the geography and the controls in under a page. Committees are time-poor. A file that answers their questions in their own sequence gets read; a file that makes them hunt gets deferred, and deferred applications quietly die.

A peptide business can have flawless documents, clean processing history and a properly licensed supply chain, and still be terminated within a month because of one sentence on a landing page. Claims risk is the dominant post-approval failure mode in this industry, and it is entirely self-inflicted.

The mechanism is simple. Acquirers and their scheme integrity vendors run automated content monitoring across their merchant portfolios. Crawlers pull your site, your checkout pages, your affiliate pages and sometimes your social channels, and score the language against a claims taxonomy. A cosmetic merchant whose page says a peptide serum "reduces the appearance of fine lines" is fine. The same merchant saying it "regenerates collagen production and heals damaged tissue" has just made a drug claim about a cosmetic product, and the monitoring flags it.

For research-use catalogues the line is harder and the enforcement is stricter. The moment an RUO site suggests a dosing protocol for a human, publishes a "how to reconstitute for injection" guide aimed at consumers, hosts before-and-after body composition photographs, describes benefits in the second person, or lets an affiliate do any of those things on its behalf, the research-use position collapses. It does not matter that a disclaimer sits in the footer. Regulators and acquirers assess the overall impression of the page, not the smallest text on it.

Third-party surfaces count. Affiliates, influencers, resellers, comparison sites and paid media buyers are all treated as extensions of the merchant. Portfolio monitoring will find the affiliate page that promises outcomes your own site never claimed, and the enforcement lands on you. Any peptide business with an affiliate programme needs written creative rules, pre-approval of copy, periodic sweeps of live affiliate pages, and a contractual right to terminate for claims breaches — and needs to show the acquirer that this programme exists.

Testimonials and user-generated content deserve specific attention. A customer review describing a therapeutic outcome, published on your product page, is a claim you have adopted by publishing it. Review moderation is therefore a compliance function, not a marketing one, and the moderation rules should be written down and shown to the underwriter.

The remedy is a claims audit before you apply, not after you are terminated. Every page, every email in every automated flow, every ad, every affiliate template and every packaging insert is reviewed against the classification of the product it sells. Non-compliant language is rewritten. Pages that cannot be made compliant are removed or gated behind verified institutional accounts. The audit is then included in the application pack as evidence of control, which converts your biggest liability into a positive signal.

There is a commercial objection to this that is worth addressing directly: compliant copy converts worse in the short term. That is often true. It is also true that a merchant account terminated in month three, with a rolling reserve held for six months and a MATCH listing attached, destroys more value than any conversion uplift ever created. The compliant version of the business is the version that compounds.

In practice, brands that rewrite properly recover most of the conversion difference within a quarter by shifting persuasion from outcome claims to mechanism, formulation quality, third-party testing, sourcing transparency and clinician credibility. Those things are provable, and provable claims are both compliant and durable.

The architecture that works for peptide companies is layered, and every layer has a different job. Collapsing them into one relationship is what turns an ordinary processor review into an existential event.

Layer one — the operating account. A business current account at an institution that has been told exactly what you do, holds payroll, suppliers, tax and general operating expenditure, and is deliberately not the account that receives card settlement. Its stability is worth more than its features. It should be at an institution that has explicitly onboarded you with your real business description on file, because an operating account opened on a vague description is a closure waiting for its trigger.

Layer two — acquiring. One or more merchant accounts for card-not-present volume, ideally with local acquiring in each major sales market to improve issuer approval rates and reduce cross-border interchange. Peptide merchants should plan for at least two live MIDs from day one, load-balanced, even if one carries the majority of volume. The second MID is not redundancy theatre; it is the difference between a bad week and a dead company.

Layer three — alternative payment methods. Bank transfer and open banking payments, local rails in each market, and where appropriate stablecoin settlement for B2B counterparties. B2B peptide flow in particular does not need card at all — ingredient buyers, formulators and CDMO clients pay by transfer, and a transfer-first strategy for that revenue removes a large slice of the portfolio from card scheme exposure entirely.

Layer four — settlement and treasury. The account that receives acquirer settlement, separated from operating, with a documented sweep policy into operating and into a reserve buffer. This separation matters when a processor holds a reserve or delays a settlement: the operating account keeps paying suppliers and staff while the dispute is worked.

Layer five — FX and cross-border. Peptide supply chains are international almost by definition, with synthesis in one region, fill-finish in another and customers in a third. Multi-currency accounts, sensible spreads and the ability to hold rather than force-convert are ordinary treasury requirements here, not luxuries. A one-percent FX spread on a supply chain that turns over its cost base monthly is a material line item.

Layer six — contingency. A dormant but live relationship: a second operating account at a different institution in a different jurisdiction, a third acquiring relationship pre-approved but unswitched, and a documented runbook for cutting over. It costs a small maintenance fee and it is the cheapest insurance in the business.

The reason we build all six is empirical. Payment providers exit categories with little notice, sometimes for reasons that have nothing to do with the merchant — a change in scheme policy, a new sponsoring bank, a regulator's thematic review, a portfolio sale. A merchant with layers survives that as an inconvenience. A merchant with one relationship discovers on a Tuesday morning that revenue has stopped and payroll is on Friday.

Across our network of 120+ institutions, we build this stack as a package rather than as a sequence of unrelated applications, which matters because the institutions need to be compatible with each other: the acquirer must be willing to settle to the settlement bank, the settlement bank must be comfortable with the acquirer's flow description, and the operating bank must understand the intercompany transfers it will see.

The right structure for a peptide business is dictated by where the customers are, where the product is made, where the people are, and what licensing the model requires. It is not dictated by which jurisdiction has the friendliest brochure.

The old offshore playbook — an anonymous company in a zero-information jurisdiction, a nominee director, an account opened on a vague description — does not work now and has not worked for years. Banks require ultimate beneficial ownership to natural persons, and they test economic substance: do you have people, premises, contracts and decision-making where you claim to. A structure without substance is not a tax strategy; it is a decline reason and, increasingly, a regulatory problem.

What does work is aligning the structure with the operating reality. If most of your customers are in the United States and your product ships from a US facility, a US operating company with US acquiring is the strongest position, because local acquiring produces better issuer approval rates and the licensing conversation happens in one legal system. If you supply ingredients from Asia to European formulators, an entity in a credible trading jurisdiction with genuine trade documentation and multi-currency banking is the right shape. If you run a clinician-led model, the entity must sit where the licensure sits — you cannot separate a regulated healthcare activity from the jurisdiction that licenses it.

Group structures earn their keep when they separate risk. A common and defensible shape is a holding company owning three operating subsidiaries: one for the cosmetic brand, one for the B2B ingredient business, and one for the research catalogue. Each subsidiary contracts separately, banks separately, processes separately and can be wound down or sold without contaminating the others. Intercompany agreements and transfer pricing need to be real and documented, because the first question a bank asks about intercompany flow is why it exists.

Jurisdictional reputation is a live variable in underwriting. Some jurisdictions add friction to every subsequent banking conversation for the life of the company, regardless of how legitimate the business is. That friction is a real cost and should be priced into the incorporation decision rather than discovered afterwards. Where a client already sits in a difficult jurisdiction, the options are to add a credible operating entity elsewhere or to redomicile, and both are ordinary projects.

Ownership visibility is a related decision. Founders sometimes want distance between their name and a category they expect to be misunderstood. Distance achieved through opacity fails at onboarding. Distance achieved through a clean holding structure with disclosed UBOs, professional directors with real authority, and a separately branded operating entity achieves the commercial objective without triggering the compliance one.

Tax structuring belongs in the same conversation but should never lead it. A structure optimised purely for tax, with no banking viability, produces a company that saves on paper and cannot collect money in practice. We sequence it the other way: bankability first, then efficiency inside the bankable shape, with local advice in each relevant jurisdiction. This is general information rather than tax or legal advice, and every structure should be confirmed by qualified advisers in the jurisdictions concerned.

Finally, licensing drives structure more than anything else in the prescriber-led and pharmacy models. Pharmacy licences, wholesale distribution authorisations, facility registrations and clinician credentials are entity-specific and often state- or country-specific. The structure has to be built around the licence map, and the licence map is the first thing we draw.

Peptide merchants are priced as high risk in card acquiring, and it is worth understanding exactly what that means so the terms can be negotiated rather than accepted.

Discount rate. Higher than mainstream retail, and driven by chargeback expectations, refund behaviour, average ticket, cross-border share and the acquirer's own sponsorship costs. The headline rate is the least important number in the term sheet; the all-in cost including scheme fees, transaction fees, gateway fees, chargeback fees, refund fees, monthly minimums and settlement charges is what you actually pay.

Rolling reserve. A percentage of settlement held for a defined period, released on a rolling basis, protecting the acquirer against future chargebacks on transactions already processed. Typical structures run from a low single-digit percentage to the mid-teens, held for three to six months. This is negotiable on three axes — percentage, hold period, and whether it steps down after a clean performance window — and the step-down is usually the easiest concession to win because it costs the acquirer nothing if you perform.

Settlement delay. Daily, weekly or longer. Working capital lives here, and a merchant with tight inventory cycles should trade a slightly higher rate for faster settlement rather than the reverse.

Volume caps. Monthly processing limits that constrain growth, usually reviewed after a performance period. Agree the review mechanism in writing at signing, including what evidence triggers an increase, or you will spend months requesting one.

Chargeback thresholds and remediation. The contractual ratio at which the acquirer can impose fees, raise reserves or terminate. Know the number, monitor against it weekly, and have a written remediation plan ready before it is asked for.

The way to improve every one of these terms is competitive tension and evidence. A merchant presenting twelve months of clean processing data, a claims-audited site, a documented fraud stack and two other offers on the table negotiates from a completely different position than one presenting a hopeful email. Even pre-revenue merchants improve terms materially by presenting the operator's track record from a prior business, a conservative forecast, and a reserve proposal of their own — offering a structured reserve before it is demanded frequently produces a lower one.

Beware the intermediaries who promise instant approval at unrealistic rates for any peptide business. The pattern is familiar: rapid boarding onto an aggregated MID under a loose description, three good months, then a termination and a frozen balance when the portfolio is reviewed. The recovery from that is far more expensive than the delay of doing it properly, particularly if a MATCH listing results.

Pricing also improves structurally when card is not doing all the work. Shifting B2B revenue to transfer, offering bank-transfer discounts on high-ticket consumer orders, and adding local payment methods in each market reduces both blended cost and scheme exposure at the same time.

Chargeback ratio is the number that determines whether your accounts survive. Everything else can be perfect, and a ratio above threshold will still end the relationship. In this vertical the disputes cluster into a handful of predictable causes, and each has a specific control.

Unrecognised descriptor. The largest single cause and the easiest to fix. Brand token in the descriptor, working phone number, and a pre-charge email that tells the customer exactly what will appear on their statement.

Delivery failure and customs seizure. International shipments of temperature-sensitive or restricted goods get delayed, damaged or held. Tracked shipping with delivery confirmation, proactive status notifications, correct customs documentation, and clear jurisdictional shipping restrictions enforced at checkout rather than after payment.

Subscription friction. Recurring billing is the highest-risk element of any peptide consumer model. Renewal reminders sent before the charge, one-click cancellation that genuinely works, no negative-option enrolment, clear and prominent renewal terms at the point of sale, and generous prorated refunds on missed cancellations. The revenue preserved by making cancellation hard is always less than the cost of the disputes it generates plus the account it eventually loses.

Expectation mismatch. Disputes filed because the product did not do what the customer believed it would. This is the claims problem arriving through a second door: compliant copy reduces chargebacks directly, because customers who were sold accurately dispute less.

Friendly fraud and true fraud. Address and card verification, device fingerprinting, velocity rules, 3-D Secure applied intelligently rather than universally, and blocklists maintained across MIDs. Peptide merchants attract card testing because the products are small, high value and shippable, so bot mitigation at checkout matters.

The operational discipline that keeps the ratio down is unglamorous: refund quickly and without argument when a customer is unhappy, because a refund costs the margin while a chargeback costs the margin plus a fee plus a point on the ratio; respond to every retrieval request with full evidence within the window; deploy Ethoca and Verifi-style alert networks so disputes can be refunded before they become chargebacks; and review the ratio weekly, per MID, against the contractual threshold rather than monthly in arrears.

Customer service is a compliance control in this business. Response times under a few hours, a real phone number, and staff empowered to refund without escalation collectively remove a large fraction of disputes before they are filed. Underwriters ask about it because they know this, and a documented service SLA in the application pack is a genuine differentiator.

The target to run against is comfortably below the scheme thresholds rather than just under them, because the thresholds are measured on ratios that move sharply when volume dips. A merchant sitting just under the line in a good month is over it in a slow one, and the remediation programme that follows is expensive in both fees and attention.

This is the pack we assemble for peptide clients. Assembling it takes one to three weeks and it is the reason approvals happen in weeks rather than never.

Corporate. Certificate of incorporation, memorandum and articles, register of directors and shareholders, UBO declaration to natural persons with ownership percentages, group structure chart, proof of registered and trading address, tax identification numbers, and any redomiciliation or name-change history.

Individuals. Passport and second identity document for each UBO and director, proof of residential address dated within three months, curriculum vitae showing relevant industry experience, source of wealth narrative with supporting evidence, and disclosure of any prior account closures, scheme listings or regulatory actions.

Licensing and regulatory. Pharmacy licences, wholesale distribution authorisations, facility registrations, clinician licences and collaboration agreements, import and export permits, and any quality certifications covering the manufacturing sites you use.

Product. Full SKU list with regulatory classification per SKU, specification sheets, certificates of analysis from accredited laboratories, label artwork, packaging inserts, safety data sheets where applicable, and supplier agreements with the manufacturers.

Commercial. Website screenshots including checkout and policy pages, sample invoices and purchase orders, top-customer and top-supplier lists with contract copies, fulfilment and logistics agreements, and the affiliate or reseller agreement template with its creative rules.

Financial. Last two years of financial statements or management accounts, six to twelve months of bank statements across all existing accounts, twelve months of processing statements with volume, refund and chargeback detail by month, and a twelve-month forecast with the assumptions written down.

Compliance. AML and KYC policy proportionate to the model, sanctions and screening approach, shipping restriction matrix by jurisdiction, age and eligibility verification method, claims policy and the results of the claims audit, refund and cancellation policy, privacy policy and data handling summary, complaints procedure, and the names and contact details of whoever owns compliance.

Resilience. A short business continuity note covering what happens if the primary processor exits: which secondary relationship takes the volume, how quickly, and who executes the switch.

Presented as a single indexed pack with a one-page executive summary at the front, this converts an application from a research project into a verification exercise. Underwriters reward that, and the reward shows up as faster approvals, lower reserves and higher volume caps.

Peptide banking projects have a rhythm. Knowing it prevents the two classic mistakes: giving up in week three because nothing has happened, and launching marketing spend against a rail that has not been confirmed.

Weeks one to two — assessment and classification. Model statement, SKU classification, claims audit, licence map, structure review, and an honest assessment of what will and will not be approvable as currently configured. This is also where we identify anything that has to change before an application goes out, because applying with a known defect burns an institution you may want later.

Weeks two to four — remediation and pack build. Website and copy fixes, policy pages rewritten, entity or website separation where the models are commingled, document pack assembled and gaps closed. Most of the client's work happens here, and the speed of this phase determines the speed of everything after it.

Weeks three to six — routing and submission. Institutions selected against the model rather than sprayed, files submitted in a deliberate sequence, and the primary and contingency tracks run in parallel rather than one after the other. Sequencing matters because declines are visible: institutions ask whether you have been declined elsewhere, and a scatter-gun approach produces a history that has to be explained.

Weeks four to eight — underwriting and questions. Committee review, follow-up questions, sometimes a call with the operator, occasionally a site visit for manufacturing models. Answering within twenty-four hours keeps a file at the top of the queue; a week's delay pushes it behind everything else and can require the credit refresh to be redone.

Weeks six to ten — approval, terms and boarding. Term sheets negotiated, reserves and caps agreed, technical integration, descriptor testing, test transactions, and a controlled volume ramp rather than an immediate switch of full traffic. Ramping matters: acquirers monitor early behaviour closely and a sudden spike above forecast triggers reviews.

Weeks eight to twelve — contingency and treasury. Second acquiring relationship established, operating and settlement accounts separated, FX arrangements set, sweep policy documented, and the continuity runbook written and tested.

Cosmetic and B2B ingredient models frequently complete faster than this. Prescriber-led models can take longer where licensing verification is involved. Research catalogues selling to consumers by card are the hardest and require the most remediation, and are sometimes best restructured toward institutional B2B before any application is made.

Throughout, the honest framing is this: institutions decide independently, and no adviser can guarantee an outcome. What preparation and routing change is the probability, the speed, and the terms — and across a portfolio of applications those three variables are the whole game.

Many peptide operators come to us mid-crisis: an acquirer has terminated with thirty days' notice, a bank has frozen an account pending review, or an application has been declined and nobody will say why. All three are workable, and all three get worse with delay.

On a frozen or restricted account. Ask, in writing, for the specific information the institution needs, and provide it completely rather than in instalments. Do not move residual balances in a hurry — sudden outbound movement during a review reads as asset flight and converts a review into a report. Assume the review is about source of funds or an unexplained counterparty until told otherwise, and prepare that evidence proactively.

On a processor termination. Establish whether it is a portfolio decision, a threshold breach, or a claims finding, because the remedy differs entirely. Portfolio exits carry no stigma and simply require rerouting. Threshold breaches require a remediation record showing the ratio coming down. Claims findings require the copy to be fixed and evidenced before a new application, because the next acquirer's monitoring vendor will crawl the same pages.

On a MATCH listing. Listings are made by the terminating acquirer under a defined reason code and persist for five years. They are not automatically fatal: some acquirers underwrite listed merchants with the story documented, and incorrect listings can be challenged with the listing acquirer. What is fatal is applying elsewhere without disclosing it, because the listing is checked at boarding and non-disclosure ends the application and often the relationship.

Preserve continuity while you fix it. If a secondary rail exists, move volume in a controlled way. If it does not, prioritise bank transfer and invoicing for the highest-value orders immediately, notify subscription customers before a failed renewal turns into a dispute, and slow marketing spend rather than driving traffic into a checkout that may fail.

Rebuild the file properly. Recovery applications are underwritten harder than first applications, so the pack has to be stronger: full disclosure of the prior event with dates and reason codes, evidence of what changed, before-and-after claims documentation, updated policies, and a chargeback trend showing improvement. Presented that way, a termination becomes a credibility story rather than a red flag.

The operators who recover fastest are the ones who treat the event as a systems failure and fix the system. The ones who chase another quick MID through an intermediary usually repeat the cycle within a year, and each cycle makes the next placement harder.

We handle recovery cases regularly, including account closures at neobanks and mainstream providers that never underwrote the category properly in the first place. In most of those cases the business was always bankable — it had simply been onboarded somewhere that was never going to keep it.

Once the base is stable, the questions change from survival to efficiency. Peptide businesses that scale well tend to make the same set of moves.

Local acquiring per market. As volume in a market passes a meaningful monthly threshold, local acquiring in that market improves issuer approval rates by several points and reduces cross-border interchange. On consumer volume, an approval-rate improvement is usually worth more than a rate reduction, because declined transactions are lost revenue rather than a cost line.

Payment method localisation. Bank transfer and open banking in Europe, local wallets in Asia, and domestic card schemes where they dominate. Every method added that is not a card removes exposure from the scheme monitoring layer while usually costing less.

B2B channel development. Selling to clinics, formulators, distributors and contract manufacturers shifts revenue onto invoice-and-transfer rails with larger tickets, negligible chargeback risk and better working capital dynamics. For most peptide groups this is both the highest-margin and the most bankable revenue in the business, and it is systematically under-invested in relative to consumer marketing spend.

Treasury discipline. Multi-currency holding rather than forced conversion, hedging where the supply chain and revenue currencies diverge materially, a written reserve buffer policy sized against the largest plausible processor hold, and a sweep schedule that keeps operating cash separate from settlement flow.

Relationship management. Institutions are not vending machines. Quarterly updates to your bank and acquirer covering volume trends, new products, new markets and any regulatory developments prevent the surprises that trigger reviews. A merchant who tells their acquirer before launching a new product line is treated very differently from one whose acquirer discovers it through monitoring.

Audit readiness. Keep the document pack current. Refresh certificates of analysis, licences, statements and screenshots on a schedule, so that a periodic review or a new application is a matter of sending a folder rather than rebuilding one under time pressure.

Contingency maintenance. Run a small amount of live volume through the secondary rail every month. A dormant MID that has never processed is not a contingency; it is an assumption. Live volume keeps it boarded, keeps the integration working and proves the cutover.

These are ordinary corporate finance and treasury practices. What makes them worth stating is that peptide operators, having spent years being treated as unbankable, often build the business around scarcity — one account, one processor, no buffer — and then find that the constraint they were designing around was solvable all along.

Risk appetite is geographic. The same peptide business is routine in one market and unplaceable in another, so knowing where your revenue sits changes which institutions we approach first.

United States. The largest peptide market and the most nuanced. Prescriber-led and pharmacy-dispensed models have deep, established acquiring options because they underwrite as healthcare. Cosmetic peptide brands board conventionally. Research-use catalogues selling direct to consumers by card are the hardest placement in the world right now, and the practical answer is almost always to develop the institutional B2B channel and shift consumer volume toward bank transfer while the card position is rebuilt. US-domiciled entities with US acquiring get materially better issuer approval rates on US cardholders, which usually outweighs any rate saving from acquiring elsewhere.

United Kingdom and European Union. Cosmetic peptides are straightforward where labelling and claims follow cosmetic regulation. Ingredient and API supply banks as B2B chemicals trade and is generally easy to place with proper documentation. Consumer-facing research catalogues face strong scrutiny and open banking or bank transfer often becomes the primary rail rather than a supplement. Strong consumer-protection expectations mean subscription and cancellation practices are examined closely at underwriting.

Gulf and wider Middle East. Strong appetite for B2B trade, ingredient distribution and manufacturing flows with credible documentation, and increasingly capable multi-currency corporate banking. Consumer health claims are policed tightly, so the marketing side needs to be conservative. For groups with regional substance, this is often where the treasury and trade layer sits even when sales are elsewhere.

Asia. Manufacturing, synthesis and ingredient supply dominate. The banking requirement here is trade finance, correspondent access, FX and cross-border settlement rather than card acquiring. Documentation quality — purchase orders, bills of lading, customs paperwork, certificates of analysis — is the entire underwriting conversation, and companies that keep it clean bank comfortably.

Latin America and other emerging markets. Local payment methods dominate consumer conversion and cards are a minority rail. Placement is about local acquiring partners and alternative methods rather than a single global MID.

Two rules apply everywhere. First, sell where you can legally ship, and enforce that at checkout rather than after the money moves — a blocked or seized shipment is a guaranteed chargeback and a compliance flag at the same time. Second, do not let a single acquirer carry more than one region's worth of your revenue if you can avoid it; geographic diversification of rails is as valuable as diversification of institutions.

Because our network spans 19 jurisdictions, the routing decision is usually not "who will take this" but "which combination gives the best approval rates, the lowest blended cost and the least correlated risk" — and those are three different answers that have to be balanced deliberately.

Underwriting conversations move faster when both sides use the same words. These are the terms that come up in every peptide banking file, defined plainly.

MID (merchant identification number). Your individual merchant account with an acquirer. Businesses at scale run several, load-balanced, so that no single termination stops revenue.

MCC (merchant category code). The four-digit code describing your business to the card schemes. Drives interchange, monitoring programme eligibility and issuer decline behaviour.

Rolling reserve. A percentage of your settlement held by the acquirer for a defined period against future disputes, released on a rolling schedule. Negotiate the percentage, the hold period and the step-down.

Chargeback ratio. Disputes as a proportion of transactions or volume in a period. The number that decides whether your account survives. Track it weekly per MID against the contractual threshold.

MATCH list. The card-scheme database of merchants terminated by an acquirer, with a reason code, persisting five years. Always disclose a listing on new applications; concealment is discovered at boarding.

Descriptor. The text on the cardholder's statement. A recognisable brand token plus a working phone number is one of the cheapest chargeback reductions available.

RUO (research use only). Product sold strictly for laboratory research, not human or veterinary use. The position must be consistent across labelling, site copy, support responses and affiliate material or it collapses.

CoA (certificate of analysis). Accredited laboratory documentation of identity, purity and content for a batch. Required in almost every peptide file, and increasingly a marketing asset because it is provable.

GMP and CDMO. Good manufacturing practice, and contract development and manufacturing organisation. Relevant where you manufacture or where your supplier does, and a strong positive signal in underwriting.

503A and 503B style compounding. Patient-specific compounding versus outsourcing-facility production. The distinction determines the licence set, and therefore the entity structure and the banking route.

UBO (ultimate beneficial owner). The natural persons who ultimately own or control the company. Must be disclosed to the individual, with identity and source of wealth evidence. Nominee-obscured ownership is a decline.

Transaction laundering. Processing sales through a MID boarded for a different business or description. Treated as fraud by the schemes, with termination, fines and listing as consequences. There is no version of this that is worth the short-term revenue.

Load balancing and cascading. Distributing transactions across multiple MIDs, and retrying declined transactions on an alternative rail. Legitimate when every MID is boarded for the business it is processing, and a core resilience technique when it is.

Operators who use this vocabulary correctly in their first conversation with an institution are read as professional counterparties rather than as applicants who need educating — and that perception measurably affects both speed and terms.

We are an advisory firm. We do not issue accounts, we do not underwrite, and we do not decide outcomes. What we do is make businesses legible to institutions and route them to the ones whose written risk appetite matches the model — across a network of more than 120 banking, EMI, acquiring and payment institutions in 19 jurisdictions.

Assessment first. Within 48 hours of receiving your structure, product list, geography and volumes, we tell you what is placeable as configured, what has to change first, and roughly what terms to expect. If we do not think we can help, we say so at that point rather than after taking a fee.

Remediation. Claims audit, product classification, entity and website separation, policy drafting, and the document pack. This phase is where most of the value is created, because it is what converts a declined application into an approved one.

Routing. Institutions selected against your specific model rather than a generic list, applications sequenced deliberately, and primary plus contingency tracks run in parallel. We know which institutions currently onboard cosmetic peptide brands, which take prescriber-led telehealth, which handle B2B ingredient exporters, and which will not touch consumer research catalogues under any circumstances — and that knowledge saves months of declines.

Negotiation. Reserves, hold periods, step-downs, volume caps, settlement timing and the review mechanisms that let terms improve as you perform. Competitive tension across parallel applications is what makes this possible.

Architecture. Operating, settlement, acquiring, FX and contingency built as one compatible stack rather than five unrelated applications, with the continuity runbook written before you need it.

Ongoing. Quarterly reviews, new-market placements as you expand, and rapid response if a relationship is reviewed or exited.

The honest boundary: institutions decide independently, timelines vary, and nobody can guarantee an approval. Some businesses are not placeable in their current form, and the useful thing an adviser can do in that case is say so early and explain precisely what would have to change. Everything here is general information rather than legal, tax, regulatory or investment advice, and licensing questions should be confirmed with qualified counsel in each relevant jurisdiction.

If you run a peptide business — research supply, compounded and prescriber-led, cosmetic, ingredient distribution or contract manufacturing — send us the structure, the product list, the markets you sell into and your current processing position. We will come back with a placement plan you can act on.